Best GLP-1 Medications in Florida: 2026 Guide

Last updated: April 2026

Florida has become one of the largest markets for GLP-1 receptor agonist medications in the United States. With roughly 22.5 million residents -- and an adult obesity rate of 29.4% according to the CDC's 2024 Behavioral Risk Factor Surveillance System -- demand for effective weight loss medications is surging across the state. Nationally, 12.4% of U.S. adults now report taking a GLP-1 medication, up from just 5.8% in February 2024. In Florida specifically, the combination of a large Medicare population, widespread telehealth adoption, and dozens of weight loss clinics from Jacksonville to Key West makes the state a bellwether for GLP-1 access nationwide.

But choosing the right GLP-1 medication in Florida isn't straightforward. Pricing, insurance formularies, clinic availability, and even which medications your pharmacy stocks can vary dramatically depending on where you live and what coverage you carry. This guide breaks down everything Florida residents need to know in 2026 -- medication by medication, city by city, and dollar by dollar.

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonist medications require a prescription and should only be used under the supervision of a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication.

Affiliate Disclosure: Some links in this article may be affiliate links. We may earn a commission if you purchase through these links, at no extra cost to you. This does not influence our editorial recommendations.

---

What Are GLP-1 Medications and How Do They Work?

GLP-1 receptor agonists mimic a natural hormone called glucagon-like peptide-1. Your gut releases GLP-1 after you eat. It tells your pancreas to produce insulin, slows stomach emptying, and signals your brain that you're full. The medications amplify this process to a degree your body can't achieve on its own.

The result: patients eat less, feel satisfied sooner, and -- in clinical trials -- lose significant amounts of body weight. In the STEP 1 trial published in the New England Journal of Medicine in 2021, patients on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. Tirzepatide, which acts on both GLP-1 and GIP receptors, showed even more dramatic results in the SURMOUNT-1 trial (2022), with the highest dose producing average weight loss of 22.5% of body weight.

These aren't cosmetic drugs. The FDA approved them for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like type 2 diabetes, high blood pressure, or high cholesterol. In 2023, the SELECT trial demonstrated that semaglutide reduced major cardiovascular events by 20% in overweight adults -- a finding that fundamentally changed how insurers and Medicare view these medications.

For Florida residents, the practical question isn't whether GLP-1s work. The science is settled. The real question is which medication fits your body, your budget, and your lifestyle. That depends on several factors we'll cover in detail below.

How GLP-1s Differ From Traditional Weight Loss Drugs

Older weight loss medications -- phentermine, orlistat, naltrexone/bupropion -- either suppress appetite through stimulant mechanisms or block fat absorption. They produce modest results (typically 5-7% body weight loss) and often carry cardiovascular risks or uncomfortable gastrointestinal side effects.

GLP-1 receptor agonists work through a fundamentally different pathway. They target the body's own incretin system, which regulates blood sugar and appetite simultaneously. This dual action is why GLP-1s are approved for both type 2 diabetes management and chronic weight management -- they address the metabolic dysfunction underlying both conditions.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "GLP-1 receptor agonists represent the most significant advance in obesity treatment in decades. For the first time, we have medications that produce weight loss approaching what we see with bariatric surgery, but without the surgical risks."

The newest development in 2026 is the arrival of oral GLP-1 medications that don't require injections at all. The FDA approved the first oral GLP-1 for weight loss in late 2025, and within three weeks of the January 2026 U.S. launch, approximately 170,000 patients had already filled prescriptions for the new pills. This is reshaping the conversation in Florida, where many patients who were reluctant to self-inject are now exploring GLP-1 treatment for the first time.

---

Which GLP-1 Medications Are Available in Florida in 2026?

Florida patients currently have access to every FDA-approved GLP-1 medication on the market. Here's a comprehensive breakdown of each option, including what makes it unique, who it's best for, and what you'll pay.

Semaglutide Injections: Wegovy and Ozempic

Wegovy (semaglutide 2.4 mg) is the most well-known GLP-1 for weight loss. It's a once-weekly injection that earned FDA approval for chronic weight management in June 2021. The maintenance dose is 2.4 mg, reached through a five-month titration schedule starting at 0.25 mg.

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg) is FDA-approved for type 2 diabetes, not weight loss. However, many Florida physicians prescribe it off-label for weight management, particularly when insurance covers the diabetes indication but not the weight loss indication. The maximum dose is 2 mg -- lower than Wegovy's 2.4 mg.

Florida pricing (April 2026):

• Wegovy without insurance: approximately $1,349/month (list price)
• Ozempic without insurance: approximately $935/month (list price)
• With commercial insurance (preferred formulary): $25-$150/month copay
• Novo Nordisk savings card (eligible commercial patients): as low as $0/month for up to 13 refills

Best for: Patients with strong commercial insurance coverage, those who qualify for the Novo Nordisk savings program, and patients who want the most extensively studied GLP-1 option. Wegovy's SELECT trial cardiovascular data gives it a unique advantage for patients with heart disease risk.

Wegovy supply shortages that plagued Florida pharmacies through 2023 and 2024 have largely resolved. As of April 2026, all dose strengths are available at most major Florida pharmacy chains including CVS, Walgreens, and Publix pharmacies. However, the Wegovy savings card has been a moving target in 2026 -- check the NovoCare website for current eligibility before assuming you qualify.

Tirzepatide Injections: Zepbound and Mounjaro

Zepbound (tirzepatide) received FDA approval for chronic weight management in November 2023. It's a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin pathways instead of one. In head-to-head data from the SURMOUNT-5 trial, tirzepatide produced greater weight loss than semaglutide -- an average of 20.2% body weight loss vs. 13.7% for semaglutide over 72 weeks.

Mounjaro (tirzepatide) is the same molecule, FDA-approved for type 2 diabetes. Like Ozempic vs. Wegovy, the diabetes version is sometimes prescribed off-label for weight loss.

Florida pricing (April 2026):

• Zepbound without insurance: approximately $1,059/month (list price)
• Mounjaro without insurance: approximately $1,023/month (list price)
• Eli Lilly's Zepbound vial program: $399/month (cash pay, no insurance needed)
• With commercial insurance (preferred formulary): $25-$150/month copay
• Zepbound savings card: as low as $0/month for eligible commercially insured patients

Best for: Patients seeking maximum weight loss, those without insurance coverage (the Zepbound vial program at $399/month is the cheapest brand-name GLP-1 option), and patients who haven't responded adequately to semaglutide alone.

Eli Lilly's direct-to-consumer vial program has been a game-changer for uninsured Florida patients. The $399/month self-pay price for Zepbound vials (which require drawing the medication with a syringe rather than using a pre-filled pen) is roughly $600-$900 cheaper per month than other brand-name options at list price. Multiple Florida telehealth providers now specialize in prescribing through this program.

Oral Semaglutide: Rybelsus and New Oral Options

Rybelsus (oral semaglutide, 7 mg or 14 mg) has been available for type 2 diabetes since 2019. It requires taking the pill on an empty stomach with no more than 4 ounces of water, then waiting at least 30 minutes before eating or drinking anything else. The maximum dose (14 mg) produces more modest weight loss than injectable semaglutide -- typically 5-8% of body weight.

New oral GLP-1 medications (2026) have changed the landscape dramatically. The FDA approved higher-dose oral semaglutide (25 mg and 50 mg) for weight management, and early prescribing data shows explosive uptake. These higher-dose oral formulations produce weight loss much closer to the injectable versions. In clinical trials, oral semaglutide 50 mg produced approximately 15.1% body weight loss over 68 weeks.

Florida pricing (April 2026):

• Rybelsus without insurance: approximately $935/month
• New oral semaglutide (weight loss formulation) introductory pricing: $149/month for the first two months through Novo Nordisk's launch program (through August 31, 2026), then $299/month
• With commercial insurance: $25-$150/month copay

Best for: Patients who can't tolerate injections, those who travel frequently (pills are easier to store than injectables), and anyone new to GLP-1 therapy who wants to start with the least intimidating option.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, noted at the 2026 Obesity Week conference: "The oral GLP-1 formulations remove one of the biggest barriers to treatment initiation. In my practice, at least 30% of patients who were hesitant about injections have now started oral therapy."

Compounded Semaglutide: What Florida Patients Need to Know

Compounded semaglutide has been one of the most controversial GLP-1 topics in Florida. During the FDA-declared shortage period (2022-2024), compounding pharmacies were legally permitted to produce copies of semaglutide at significantly lower prices -- often $200-$400/month.

As of 2026, the legal landscape has shifted. The FDA declared the semaglutide shortage resolved in late 2024, which means 503A compounding pharmacies can no longer legally compound copies of brand-name semaglutide. Some 503B outsourcing facilities continue to operate, but enforcement actions are ongoing.

The bottom line for Florida patients: If someone is offering you "compounded semaglutide" at a dramatically lower price, ask questions. Is the pharmacy a registered 503B outsourcing facility? Can they show FDA registration? Florida's Board of Pharmacy has issued multiple warnings about unregistered sellers operating online.

For a complete breakdown of what's legal and what isn't, read our compounded semaglutide guide.

---

How Much Do GLP-1 Medications Cost in Florida Without Insurance?

Cost is the single biggest barrier to GLP-1 access in Florida. A 2025 KFF poll found that 14% of GLP-1 users stopped taking their medication specifically because of drug costs, and roughly half of all adults surveyed said these medications are difficult to afford.

Here's what you'll pay in Florida in April 2026 without any insurance coverage:

Medication	Monthly List Price	Best Cash-Pay Price	Notes
Wegovy (semaglutide 2.4 mg)	~$1,349	~$1,100 (GoodRx coupon)	Novo Nordisk savings card for eligible patients
Ozempic (semaglutide 1-2 mg)	~$935	~$800 (GoodRx coupon)	Off-label for weight loss
Zepbound (tirzepatide) pen	~$1,059	~$900 (GoodRx coupon)	Eli Lilly savings card available
Zepbound vials	$399	$399 (direct from Lilly)	Best uninsured option
Mounjaro (tirzepatide)	~$1,023	~$850 (GoodRx coupon)	Off-label for weight loss
Oral semaglutide (new, 25/50 mg)	~$1,200	$149-$299 (launch program)	Introductory pricing ends Aug 2026
Rybelsus (oral semaglutide 14 mg)	~$935	~$800 (GoodRx coupon)	Lower weight loss vs. injectables

Florida-Specific Savings Strategies

Costco Pharmacy: Florida Costco locations consistently offer some of the lowest cash-pay prices for GLP-1 medications. You don't need a Costco membership to use their pharmacy. Multiple Florida patients report saving $100-$200/month compared to CVS or Walgreens pricing.

Manufacturer savings programs: Both Novo Nordisk (for Wegovy/Ozempic) and Eli Lilly (for Zepbound/Mounjaro) offer savings cards that can reduce commercial insurance copays to $0-$25/month. These programs change frequently -- always verify current terms before relying on them.

Patient assistance programs: If your household income is below 400% of the federal poverty level ($62,400 for a single person in 2026), you may qualify for Novo Nordisk's Patient Assistance Program or Eli Lilly's Lilly Cares program, which provide medications at no cost.

Telehealth programs: Several Florida-based telehealth providers bundle the consultation fee with medication costs, sometimes offering all-inclusive pricing between $499 and $999/month that covers the provider visit, medication, and shipping.

---

Does Insurance Cover GLP-1 Medications in Florida?

Insurance coverage for GLP-1 medications in Florida is a patchwork. The answer depends entirely on your type of coverage, your specific plan, and whether you're seeking treatment for diabetes or weight loss.

Commercial Insurance in Florida

Most major commercial insurers operating in Florida -- including Blue Cross Blue Shield of Florida (Florida Blue), Aetna, UnitedHealthcare, Cigna, and Humana -- now cover at least one GLP-1 medication for weight loss with prior authorization. This is a significant shift from 2023, when many plans excluded weight loss medications entirely.

However, "coverage" doesn't mean "affordable." Prior authorization requirements typically demand:

• A documented BMI of 30+ (or 27+ with a comorbidity)
• Evidence of failed lifestyle interventions (diet, exercise) for 3-6 months
• Sometimes a failed trial of an older, cheaper weight loss medication first

A major development in 2026: CVS Caremark, which manages pharmacy benefits for millions of Florida residents, shifted its preferred GLP-1 formulary. According to Truveta research, this formulary change significantly altered prescribing patterns across their covered lives. If your employer uses CVS Caremark for pharmacy benefits, check whether your preferred GLP-1 is on the formulary's preferred tier -- a non-preferred status can mean the difference between a $50 copay and a $500 copay.

Florida Medicaid

Florida Medicaid does not cover GLP-1 medications for weight loss as of April 2026. The state covers semaglutide (Ozempic) and tirzepatide (Mounjaro) for type 2 diabetes management, but only the diabetes-approved indications. This leaves low-income Florida residents without diabetes facing significant barriers to GLP-1 access.

Several Florida state legislators have introduced bills to expand Medicaid coverage of anti-obesity medications. None have passed as of this writing.

For a detailed state-by-state breakdown, see our 2026 insurance coverage update.

Medicare in Florida

Medicare coverage has been the biggest GLP-1 story in 2026. Historically, Medicare Part D was barred by law from covering medications prescribed solely for weight loss. The Inflation Reduction Act didn't change this restriction.

But CMS announced the BALANCE Model and GLP-1 Bridge program in 2026, creating a pathway for Medicare beneficiaries to access GLP-1 medications at dramatically reduced cost:

• Medicare GLP-1 Bridge: Operating from July 1, 2026, through December 31, 2026, this nationwide program allows eligible Medicare beneficiaries to access GLP-1 medications for a $50/month copay.
• BALANCE Model: A longer-term model that pairs GLP-1 medication access with intensive behavioral health counseling and nutrition support.

For Florida's 4.8 million Medicare beneficiaries, this is enormous. Previously, a Medicare patient in Miami or Tampa wanting Wegovy would pay full retail price -- over $1,300/month. Starting in July 2026, eligible patients will pay $50.

Eligibility details are still being finalized. CMS has indicated the program will be available in all states and territories, but enrollment may be capped.

---

What Are the Best GLP-1 Clinics and Telehealth Providers in Florida?

Florida's GLP-1 clinic landscape is dense. From South Florida weight loss centers to Panhandle telehealth services, patients have dozens of options. Here's how to navigate them.

In-Person Weight Loss Clinics

Florida has board-certified obesity medicine specialists in every major metro area. The Obesity Medicine Association directory lists over 200 certified providers in the state. Major hospital systems -- including AdventHealth (Orlando), Baptist Health (South Florida), Tampa General Hospital, and Mayo Clinic Jacksonville -- all have dedicated weight management programs that prescribe GLP-1 medications.

What to look for in a Florida GLP-1 clinic:

• Board-certified physician (look for ABOM certification in obesity medicine)
• Comprehensive metabolic assessment (not just a weight check and a prescription)
• Nutritional counseling and exercise programming included
• Lab monitoring (A1C, metabolic panel, thyroid function)
• Clear pricing disclosed upfront -- if they won't tell you costs before your visit, walk away

What to avoid:

• Med spas or aesthetic clinics that added GLP-1 prescribing as a revenue stream without obesity medicine expertise
• Providers who skip the titration schedule and start at high doses
• Any clinic selling compounded semaglutide without clear documentation of their pharmacy's FDA registration status

Telehealth Options for Florida Residents

Florida's telehealth laws are relatively permissive. Board-certified physicians can prescribe GLP-1 medications to Florida patients via video consultation without requiring an in-person visit. This has made telehealth the fastest-growing channel for GLP-1 prescriptions in the state.

National telehealth platforms serving Florida:

• Ro (Roman): Prescribes brand-name and compounded GLP-1 options. Monthly membership model.
• Hims & Hers: Offers semaglutide and tirzepatide programs with all-inclusive pricing.
• Found: Focuses on obesity medicine with board-certified specialists. Insurance billing available.
• Calibrate: Year-long metabolic health program pairing GLP-1 prescriptions with coaching.

Florida-specific telehealth providers:

• Florida Weight Loss MD: Online bariatric clinic offering same-day GLP-1 prescriptions to Florida residents with virtual appointments.
• GLP1Florida.com: Telehealth service operating across all Florida counties, prescribing semaglutide and tirzepatide.
• Phoenix Medical Group FL: Telehealth-first weight loss practice with GLP-1 prescribing for Florida patients.
• TrimRX: Southeast-focused telehealth provider serving Florida, Georgia, North Carolina, and South Carolina.

Pricing for telehealth programs ranges widely. Some charge a flat consultation fee ($99-$199) and send prescriptions to your local pharmacy, where you pay separately. Others bundle everything -- consultation, medication, and shipping -- for $499-$999/month. The bundled programs often include compounded formulations, so ask exactly what medication you're receiving.

City-by-City Access in Florida

Miami/Fort Lauderdale: The densest concentration of GLP-1 providers in the state. South Florida has more than 60 weight loss clinics prescribing GLP-1 medications. Competition drives pricing lower here than in rural areas. Multiple independent pharmacies in Miami-Dade County stock all GLP-1 formulations.

Tampa/St. Petersburg: A growing GLP-1 market with strong telehealth adoption. Tampa General Hospital's weight management program is one of the state's most comprehensive. ClearMetabolic lists multiple GLP-1 providers in the Tampa metro area.

Orlando: AdventHealth's Metabolic and Bariatric Institute anchors the market. Multiple telehealth providers serve the Central Florida corridor.

Jacksonville: Mayo Clinic's Jacksonville campus has a dedicated obesity medicine program. Northeast Florida generally has fewer providers than South Florida, making telehealth an important supplemental option.

Southwest Florida (Fort Myers, Naples): A growing market driven by the region's older population. Over 28 GLP-1 clinics now operate in the Fort Myers area alone, ranging from bariatric surgery centers to primary care offices.

---

How Do You Choose the Right GLP-1 Medication for You?

Choosing between GLP-1 medications isn't as simple as picking the one with the highest weight loss numbers. Your medical history, insurance, lifestyle, and tolerance for side effects all factor in. Here's a decision framework Florida patients can use.

Weight Loss as the Primary Goal

If maximum weight loss is your main objective and you're otherwise healthy:

1. First choice: Tirzepatide (Zepbound) -- The SURMOUNT-5 head-to-head trial showed tirzepatide beats semaglutide for weight loss. Average loss of 20.2% body weight at the highest dose.
2. Second choice: Semaglutide 2.4 mg (Wegovy) -- Slightly less weight loss than tirzepatide, but the most extensive long-term safety data and proven cardiovascular benefits.
3. Third choice: Oral semaglutide 50 mg -- For patients who refuse injections. Approximately 15.1% body weight loss, which is competitive with injectable semaglutide.

Type 2 Diabetes Management

If you have type 2 diabetes, your insurance will cover the diabetes-indication versions (Ozempic, Mounjaro) much more readily than the weight loss versions:

1. Tirzepatide (Mounjaro) -- Superior A1C reduction compared to semaglutide in the SURPASS trials. Dual GIP/GLP-1 action provides better glycemic control.
2. Semaglutide (Ozempic) -- Well-established A1C reduction with cardiovascular benefit data from SUSTAIN-6 and SELECT trials.
3. Oral semaglutide (Rybelsus) -- Convenient pill form for patients with needle phobia. Adequate A1C control but less potent than injectables.

Cardiovascular Risk Reduction

If you have established cardiovascular disease or multiple risk factors:

• Semaglutide (Wegovy) is currently the only GLP-1 with an FDA-approved cardiovascular indication based on the SELECT trial. It reduced major adverse cardiovascular events (MACE) by 20%.
• Tirzepatide cardiovascular outcome data is pending from the SURPASS-CVOT trial.

Budget-Constrained Patients

If cost is your primary concern:

1. Zepbound vials: $399/month, no insurance needed
2. New oral semaglutide launch pricing: $149-$299/month through August 2026
3. Patient assistance programs: $0/month if you qualify based on income
4. Medicare GLP-1 Bridge (starting July 2026): $50/month for eligible Medicare beneficiaries

The protein-rich diet supporting your GLP-1 treatment matters too. Maintaining lean muscle mass during rapid weight loss is critical. Check our guide to the best protein powders for GLP-1 users to support your treatment.

---

What Side Effects Should Florida Patients Expect?

Every GLP-1 medication shares a similar side effect profile. Understanding what's normal, what's concerning, and when to call your doctor is essential -- especially in Florida's heat, where dehydration risk is amplified.

Common Side Effects (Experienced by 20-50% of Patients)

• Nausea: The most frequently reported side effect. Typically worst during dose escalation and improves over 4-8 weeks at each dose level. Eating smaller, more frequent meals helps.
• Diarrhea or constipation: Gastrointestinal changes are common as GLP-1 medications slow gastric emptying. Most patients experience one or the other, rarely both.
• Decreased appetite: This is the mechanism of action, not technically a side effect. But it can feel extreme, especially at higher doses. Forcing yourself to eat adequate protein (0.7-1.0 g per pound of body weight) is important to prevent muscle loss.
• Injection site reactions: Redness, itching, or bruising at the injection site. Rotating injection sites (abdomen, thigh, upper arm) reduces this.

Florida-Specific Considerations

Florida's climate creates unique challenges for GLP-1 users:

Dehydration risk: GLP-1 medications reduce appetite and can cause nausea, both of which lead to reduced fluid intake. Combined with Florida's heat and humidity (especially May through October), dehydration is a serious concern. Florida GLP-1 patients should aim for 80-100 ounces of water daily -- more if you're active outdoors.

Medication storage: Injectable GLP-1 medications must be stored in the refrigerator (36-46 degrees F) before first use. After first use, most can be stored at room temperature for up to 21-28 days. In Florida's summer heat, leaving your Wegovy pen in a hot car for even 30 minutes could degrade the medication. If you're traveling within Florida, use an insulated medication travel case.

Sun sensitivity: Some patients report increased sun sensitivity while on GLP-1 medications. There's limited clinical data on this, but Florida dermatologists recommend consistent SPF 30+ sunscreen use regardless.

Serious Side Effects (Seek Medical Attention)

• Severe abdominal pain that doesn't resolve (possible pancreatitis -- reported in roughly 0.2% of clinical trial participants)
• Signs of thyroid tumors: lump in the neck, hoarseness, difficulty swallowing (GLP-1 medications carry a boxed warning about thyroid C-cell tumors observed in rodent studies)
• Severe allergic reaction: difficulty breathing, rapid heartbeat, swelling of face or throat
• Gallbladder problems: intense upper abdominal pain radiating to the back, especially after eating fatty foods
• Kidney problems: decreased urination, swelling in legs, unusual fatigue

If you experience any of these, contact your Florida healthcare provider immediately or visit the nearest emergency room. The research on GLP-1 side effects continues to evolve -- some studies are even exploring unexpected brain health benefits alongside the known risks.

---

What's Coming Next for GLP-1 Access in Florida?

The GLP-1 landscape is shifting fast. Several developments in 2026 and beyond will directly impact Florida patients.

Medicare GLP-1 Bridge (July-December 2026)

The biggest near-term change. CMS's Medicare GLP-1 Bridge program launches July 1, 2026, offering eligible Medicare beneficiaries GLP-1 medications at $50/month. For Florida's 4.8 million Medicare enrollees, this could dramatically expand access. The program runs through December 31, 2026, and CMS has indicated it may be extended depending on outcomes data.

The BALANCE Model

CMS's BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model is a longer-term initiative pairing GLP-1 medication access with intensive behavioral counseling, nutrition support, and exercise programming. It applies to both Medicare and Medicaid populations. Florida's participation will depend on state agency enrollment, but the program is designed to be available nationwide.

Generic and Biosimilar Competition

J.P. Morgan projects that more than 30 million Americans could be on GLP-1 treatment by 2030, up from approximately 10 million in 2026. This demand is attracting generic and biosimilar manufacturers. While branded semaglutide patents extend into the late 2020s, biosimilar competition for older GLP-1 formulations could begin driving prices down in Florida pharmacies within the next 2-3 years.

Next-Generation GLP-1 Medications

Several pipeline drugs will reshape Florida's options:

• Retatrutide (Eli Lilly): A triple agonist (GLP-1/GIP/glucagon) that produced up to 24.2% body weight loss in Phase 2 trials. Phase 3 results expected in 2026.
• CagriSema (Novo Nordisk): Combines semaglutide with cagrilintide (an amylin analog) for potentially greater weight loss than semaglutide alone.
• Orforglipron (Eli Lilly): A small-molecule oral GLP-1 that doesn't require the empty-stomach restrictions of current oral semaglutide. Could be a convenience breakthrough if approved.
• Once-monthly GLP-1 injections: Multiple companies are developing formulations requiring just 12 injections per year. This would be a significant adherence improvement over current weekly dosing.

Florida Legislative Watch

Florida's legislature continues to debate GLP-1 coverage mandates. Key bills under consideration would:

• Require state-regulated insurance plans to cover at least one GLP-1 medication for weight loss
• Expand Florida Medicaid to cover anti-obesity medications
• Regulate compounding pharmacy practices related to GLP-1 medications more strictly

None of these have passed as of April 2026, but the political momentum is growing as GLP-1 usage becomes mainstream.

---

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

1. Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data (NEJM, JAMA, NCBI), FDA prescribing information, and CMS coverage criteria.
2. Patient-reported outcomes: r/Semaglutide, r/Tirzepatide, r/GLP1, and the verified GLP-1 Daily community from the past 12 months. We track patterns in supply shortages, compounding-pharmacy reports, and adverse-event clustering.
3. First-hand provider testing: editorial telehealth consults to each ranked provider verifying drug source, lab requirements, and continuity of care.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

Can I get GLP-1 medications through telehealth in Florida?

Yes. Florida law permits licensed physicians to prescribe GLP-1 medications via telehealth without an in-person visit. Multiple national and Florida-specific telehealth providers offer same-day or next-day video consultations. You'll need to provide basic health information, and some providers require recent lab work. Prescriptions can be sent to your local Florida pharmacy or shipped directly to your home, depending on the provider.

Does Florida Medicaid cover Wegovy or Zepbound for weight loss?

No. As of April 2026, Florida Medicaid covers GLP-1 medications only for type 2 diabetes (Ozempic, Mounjaro). Weight loss indications (Wegovy, Zepbound) are not covered. If you have type 2 diabetes and qualify for Medicaid, your provider may prescribe the diabetes formulation, which will also produce weight loss. Legislative efforts to expand coverage are ongoing but have not yet passed.

How long do I need to take GLP-1 medications?

Current evidence suggests GLP-1 medications work best as long-term therapy. The STEP 1 extension trial showed that patients who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Most Florida obesity medicine specialists recommend planning for indefinite treatment, similar to how you'd approach blood pressure or cholesterol medication. That said, some patients successfully maintain weight loss after stopping by combining rigorous diet, exercise, and behavioral strategies.

Are compounded semaglutide injections still legal in Florida?

The legal status is complicated. The FDA declared the semaglutide shortage resolved in late 2024, which ended the exemption allowing most compounding pharmacies (503A facilities) to produce semaglutide copies. Registered 503B outsourcing facilities may still compound under certain conditions, but enforcement actions are ongoing. If you're currently using compounded semaglutide in Florida, ask your provider about the pharmacy's registration status and have a transition plan to brand-name or other FDA-approved options.

What BMI do I need to qualify for GLP-1 medications in Florida?

The FDA-approved criteria are a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea). Florida providers follow these guidelines, and insurance companies use them for prior authorization criteria. Some telehealth providers may have slightly different eligibility thresholds for their self-pay programs. Your provider will assess your individual situation during your consultation.

---

Related Reading

• FDA Approves New Oral GLP-1 Medication in 2026: What You Need to Know
• GLP-1 Insurance Coverage Expands in 2026: State-by-State Update
• GLP-1 Medications: A New Hope for Addiction and Brain Health?
• Best Protein Powders for GLP-1 Users

---

Sources

1. KFF. "Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug." 2025. https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/
2. CMS. "Medicare GLP-1 Bridge." 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
3. CMS. "BALANCE Model." 2026. https://www.cms.gov/priorities/innovation/innovation-models/balance
4. J.P. Morgan. "How Supply and Demand for Weight Loss Drugs is Playing Out in 2026." https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
5. Truveta. "Impact of CVS GLP-1 Formulary Change on Prescribing." 2026. https://www.truveta.com/blog/research/amcp-2026-impact-cvs-glp-1-formulary-change/
6. AAMC. "GLP-1 Pills for Weight Loss Are Here." 2026. https://www.aamc.org/news/glp-1-pills-weight-loss-are-here-how-will-they-change-obesity-care
7. KFF. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid." 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
8. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989-1002.
9. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216.
10. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023;389:2221-2232.

---

-- The GLP-1 Daily Team